OKLAHOMA CITY, March 11, 2023 — Cytovance Biologics and Phenotypeca Limited (Phenotypeca), a research and development organization with proprietary yeast expression technology that provides key advantages in recombinant protein manufacture, have entered into an agreement to provide optimized Saccharomyces cerevisiae strains for biopharmaceutical manufacturing.
Cytovance Biologics and Avantor Collaborate to Accelerate Plasmid DNA Development for Global Biopharma Market. Cytovance Biologics and Avantor will accelerate plasmid production and sourcing services for new and existing viral vector and mRNA-based vaccine and therapeutic customers.
Cytovance Biologics announces the next webinar of its 2021 series: pDNA Manufacturing: An Optimized Platform Process. The webinar set for June 24, 2021 at 12pm EDT will feature a discussion on strain selection
OKLAHOMA CITY, January 16, 2023 — Cytovance Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian and microbial biologics, announces the appointment of Mr. Ping Zhang as Chief Executive Officer.